In a new paper, Ken Taymor

In a new paper, Ken Taymor looks at the E.U. regulation of biotech medicines, which are akin to branded drugs whose patents have expired. These “biosimilars” have saved billions for the E.U., but are still off the U.S. market due to FDA inaction.